Kavar Capital Partners Group LLC Cuts Stock Position in Danaher Co. (NYSE:DHR)

Kavar Capital Partners Group LLC cut its holdings in Danaher Co. (NYSE:DHR) by 1.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 46,656 shares of the conglomerate’s stock after selling 813 shares during the quarter. Danaher accounts for 2.1% of Kavar Capital Partners Group LLC’s investment portfolio, making the stock its 11th largest position. Kavar Capital Partners Group LLC’s holdings in Danaher were worth $12,971,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Vicus Capital acquired a new stake in shares of Danaher in the first quarter worth approximately $209,000. Cornerstone Wealth Group LLC acquired a new stake in shares of Danaher in the first quarter worth approximately $261,000. Breakwater Capital Group boosted its stake in shares of Danaher by 5.6% in the first quarter. Breakwater Capital Group now owns 2,353 shares of the conglomerate’s stock worth $588,000 after acquiring an additional 124 shares during the last quarter. Roberts Wealth Advisors LLC acquired a new stake in shares of Danaher in the first quarter worth approximately $256,000. Finally, LVW Advisors LLC acquired a new stake in shares of Danaher in the first quarter worth approximately $235,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Danaher news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Georgeann Couchara sold 952 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,059 shares of company stock worth $8,400,897 in the last quarter. 11.10% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on DHR. UBS Group lowered their price target on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday. KeyCorp boosted their price objective on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday. Evercore ISI boosted their price objective on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Royal Bank of Canada lowered their price objective on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, Leerink Partners boosted their price objective on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $287.28.

Danaher Price Performance

DHR stock opened at $245.39 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $181.76 billion, a PE ratio of 41.59, a P/E/G ratio of 4.49 and a beta of 0.83. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70. The business’s fifty day moving average price is $269.52 and its 200 day moving average price is $260.42.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.02 EPS. On average, sell-side analysts anticipate that Danaher Co. will post 7.59 EPS for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were issued a $0.27 dividend. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s dividend payout ratio is presently 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.